EVOK · Evoke Pharma Inc

-

Please sign in to comment on EVOK

1 Comment

Admin

4 years, 1 month ago

Evoke Pharma, Inc is currently in a long term downtrend where the price is trading 52.4% below its 200 day moving average.

From a valuation standpoint, the stock is 53.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2048.7.

Evoke Pharma, Inc's total revenue rose by inf% to $23K since the same quarter in the previous year.

Its net income has dropped by 59.9% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 49.1% to $-2M since the same quarter in the previous year.

Based on the above factors, Evoke Pharma, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US30049G2030

Beta	0.15
Market Cap	5M
PE Ratio	None
Target Price	18
Dividend Yield	None

ABOUT

Evoke Pharma Inc

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.

EVOK · Evoke Pharma Inc

-

Evoke Pharma Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Evoke Pharma Inc using a moving average strategy